The DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.
Randomized, Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis
Abstract
OBJECTIVE: This study assessed the efficacy of olanzapine in delaying or preventing conversion to psychosis and reducing symptoms in people with prodromal symptoms of schizophrenia. METHOD: This randomized trial occurred at four North American clinics in the Prevention Through Risk Identification, Management, and Education project. Outpatients received olanzapine (5-15 mg/day, N=31) or placebo (N=29) during a 1-year double-blind treatment period and no treatment during a 1-year follow-up period. Efficacy measures included the conversion-to-psychosis rate and Scale of Prodromal Symptoms scores. RESULTS: During the treatment year, 16.1% of olanzapine patients and 37.9% of placebo patients experienced a conversion to psychosis, a nearly significant difference. The hazard of conversion among placebo patients was about 2.5 times that among olanzapine-treated patients, which also approached significance. In the follow-up year, the conversion rate did not differ significantly between groups. During treatment, the mean score for prodromal positive symptoms improved more in the olanzapine group than in the placebo group, and the mixed-model repeated-measures least-squares mean score showed significantly greater improvement between weeks 8 and 28 with olanzapine. The olanzapine patients gained significantly more weight (mean=8.79 kg, SD=9.05, versus mean=0.30 kg, SD=4.24). CONCLUSIONS: A significant treatment difference in the conversion-to-psychosis rate was not demonstrated. However, these results may be influenced by low power. The nearly significant differences suggest that olanzapine might reduce the conversion rate and delay onset of psychosis. Olanzapine was efficacious for positive prodromal symptoms but induced weight gain. Further treatment research in this phase of illness is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, clinical trials have failed so far to provide clear evidence that antipsychotics can prevent conversion to schizophrenia in at-risk individuals 63 .”
From Developmental timing and critical windows for the treatment of psychiatric disorders (2016) · cites this paper as [63]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
Simpson, G. M., B., M., B., G., Angus, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,265
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · The British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,179
The number needed to treat: a clinically useful measure of treatment effect
Cook, R. J., & Sackett, D. L. (1995) · BMJ · doi:10.1136/bmj.310.6977.452 · Cited by 1,885
Miller, T. J., McGlashan, T. H., Rosen, J. L., Cadenhead, K. S., Ventura, J., McFarlane, W. R., Perkins, D. O., Pearlson, G. D., & Woods, S. W. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007040 · Cited by 1,800
Self-citationMeasurement of Premorbid Adjustment in Chronic Schizophrenia
Cannon-Spoor, H. E., Potkin, S. G., & Wyatt, R. J. (1982) · Schizophrenia Bulletin · doi:10.1093/schbul/8.3.470 · Cited by 1,220
McGorry, P. D., Yung, A. R., Phillips, L. J., Yuen, H. P., Francey, S., Cosgrave, E. M., Germano, D., Bravin, J., McDonald, T., Blair, A., et al. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.10.921 · Cited by 1,056
Global Assessment of Functioning
Hall, R. C. W. (1995) · Psychosomatics · doi:10.1016/s0033-3182(95)71666-8 · Cited by 975
Research works printed but not linked: 2
- McGlashan TH, 2001, Netherlands, Kluwer Academic, 135
- Guy, 1976, ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338
Cited by
Sorted by citations
The Psychosis High-Risk State: A Comprehensive State-of-the-Art Review
Fusar-Poli, P., Borgwardt, S., Bechdolf, A., Addington, J., Riecher-Rössler, A., Schultze-Lutter, F., Keshavan, M., Wood, S., Ruhrmann, S., Seidman, L. J., et al. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.269 · Cited by 1,483
Self-citationPredicting Psychosis: Meta-analysis of Transition Outcomes in Individuals at High Clinical Risk
Fusar-Poli, P. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.1472 · Cited by 1,361
Cannon, T. D., Cadenhead, K., Cornblatt, B., Woods, S. W., Addington, J., Walker, E., Seidman, L. J., Perkins, D., Tsuang, M., McGlashan, T., et al. (2008) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2007.3 · Cited by 1,269
Self-citationKahn, R. S., Sommer, I. E., Murray, R. M., Meyer‐Lindenberg, A., Weinberger, D. R., Cannon, T. D., O’Donovan, M. C., Correll, C. U., Kane, J. M., van Os, J., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.67 · Cited by 1,163
Amminger, G. P., Schäfer, M. R., Papageorgiou, K., Klier, C. M., Cotton, S. M., Harrigan, S. M., Mackinnon, A., McGorry, P. D., & Berger, G. E. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.192 · Cited by 896
Elevated Striatal Dopamine Function Linked to Prodromal Signs of Schizophrenia
Howes, O. D., Montgomery, A. J., Asselin, M.-C., Murray, R. M., Valli, I., Tabraham, P., Bramon-Bosch, E., Valmaggia, L., Johns, L., Broome, M., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2008.514 · Cited by 744
Ruhrmann, S., Schultze-Lutter, F., Salokangas, R. K. R., Heinimaa, M., Linszen, D., Dingemans, P., Birchwood, M., Patterson, P., Juckel, G., Heinz, A., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.206 · Cited by 632
Stress and the hypothalamic pituitary adrenal axis in the developmental course of schizophrenia
Walker, E., Mittal, V., & Tessner, K. (2008) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.4.022007.141248 · Cited by 615
Barnes, T. R. E., Drake, R., Paton, C., Cooper, S. J., Deakin, J. F. W., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I. R., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 615
The Role of Genes, Stress, and Dopamine in the Development of Schizophrenia
Howes, O. D., McCutcheon, R. A., Owen, M. J., & Murray, R. M. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.07.014 · Cited by 640
EPA guidance on the early intervention in clinical high risk states of psychoses
Schmidt, S. J., Schultze-Lutter, F., Schimmelmann, B. G., Maric, N. P., Salokangas, R. K. R., Riecher-Rössler, A., van der Gaag, M., Meneghelli, A., Nordentoft, M., Marshall, M., et al. (2015) · European Psychiatry · doi:10.1016/j.eurpsy.2015.01.013 · Cited by 585
Early intervention in psychosis: concepts, evidence and future directions
MCGORRY, P. D., KILLACKEY, E., & YUNG, A. (2008) · World Psychiatry · doi:10.1002/j.2051-5545.2008.tb00182.x · Cited by 581
An Individualized Risk Calculator for Research in Prodromal Psychosis
Cannon, T. D., Yu, C., Addington, J., Bearden, C. E., Cadenhead, K. S., Cornblatt, B. A., Heinssen, R., Jeffries, C. D., Mathalon, D. H., McGlashan, T. H., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.15070890 · Cited by 574
Self-citationEarly intervention for psychosis
Marshall, M., & Rathbone, J. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004718.pub3 · Cited by 531
Altering the course of schizophrenia: progress and perspectives
Millan, M. J., Andrieux, A., Bartzokis, G., Cadenhead, K., Dazzan, P., Fusar-Poli, P., Gallinat, J., Giedd, J., Grayson, D. R., Heinrichs, M., et al. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.28 · Cited by 516
Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis
Bak, M., Fransen, A., Janssen, J., van Os, J., & Drukker, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094112 · Cited by 490
Early interventions to prevent psychosis: systematic review and meta-analysis
Stafford, M. R., Jackson, H., Mayo-Wilson, E., Morrison, A. P., & Kendall, T. (2013) · BMJ · doi:10.1136/bmj.f185 · Cited by 456
Long-term Follow-up of a Group at Ultra High Risk (“Prodromal”) for Psychosis
Nelson, B., Yuen, H. P., Wood, S. J., Lin, A. P., Spiliotacopoulos, D., Bruxner, A., Broussard, C., Simmons, M. B., Foley, D. L., Brewer, W. J., et al. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.1270 · Cited by 434
Koutsouleris, N., Meisenzahl, E. M., Davatzikos, C. A., Bottlender, R., Frodl, T., Scheuerecker, J., Schmitt, G., Zetzsche, T., Decker, P., Reiser, M. F., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.62 · Cited by 400
Woods, S. W., Addington, J., Cadenhead, K. S., Cannon, T. D., Cornblatt, B. A., HEINSSEN, R. K., Perkins, D. O., Seidman, L. J., Tsuang, M. T., Walker, E. F., et al. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp027 · Cited by 404
Self-citationSchizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future
Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.05.025 · Cited by 405
van der Gaag, M., Smit, F., Bechdolf, A., French, P., Linszen, D. H., Yung, A. R., McGorry, P., & Cuijpers, P. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.07.004 · Cited by 384
Developmental timing and critical windows for the treatment of psychiatric disorders
Marín, O. (2016) · Nature Medicine · doi:10.1038/nm.4225 · Cited by 374
Meyer, U., Feldon, J., & Fatemi, S. H. (2009) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.05.001 · Cited by 382
Yung, A. R., Nelson, B., Baker, K., Buckby, J. A., Baksheev, G., & Cosgrave, E. M. (2009) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670802607188 · Cited by 371
Epidemiology-driven neurodevelopmental animal models of schizophrenia
Meyer, U., & Feldon, J. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.10.018 · Cited by 378
Yung, A. R., Nelson, B., Stanford, C., Simmons, M. B., Cosgrave, E. M., Killackey, E., Phillips, L. J., Bechdolf, A., Buckby, J., & McGorry, P. D. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.07.012 · Cited by 358
Barnes, T. R. E. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110391123 · Cited by 369
Mental health promotion and mental illness prevention: the economic case
Knapp, M. R. J., McDaid, D., & Parsonage, M. (2011) · London School of Economics and Political Science Research Online (London School of Economics and Political Science) · Cited by 341
Morrison, A. P., French, P., Stewart, S. L. K., Birchwood, M., Fowler, D., Gumley, A. I., Jones, P. B., Bentall, R. P., Lewis, S. W., Murray, G. K., et al. (2012) · BMJ · doi:10.1136/bmj.e2233 · Cited by 332
Progressive Gray Matter Reduction of the Superior Temporal Gyrus During Transition to Psychosis
Takahashi, T., Wood, S. J., Yung, A. R., Soulsby, B., McGorry, P. D., Suzuki, M., Kawasaki, Y., Phillips, L., Velakoulis, D., & Pantelis, C. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.12 · Cited by 328
Pruessner, M., Cullen, A. E., Aas, M., & Walker, E. F. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.12.013 · Cited by 315
Intervention in Individuals at Ultra-High Risk for Psychosis
McGorry, P. D., Nelson, B., Amminger, G. P., Bechdolf, A., Francey, S. M., Berger, G. E., Riecher‐Rössler, A., Klosterkötter, J., Ruhrmann, S., Schultze‐Lutter, F., et al. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08r04472 · Cited by 305
Howes, O., Bose, S., Turkheimer, F., Valli, I., Egerton, A., Stahl, D., Valmaggia, L., Allen, P., Murray, R., & McGuire, P. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.20 · Cited by 292
Holmes, E. C., Tsang, T. M., Huang, J. T.-J., Leweke, F. M., Koethe, D., Gerth, C. W., Nolden, B. M., Gross, S., Schreiber, D., Nicholson, J. K., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030327 · Cited by 292
McGorry, P. D., Nelson, B., Goldstone, S. D., & Yung, A. R. (2010) · The Canadian Journal of Psychiatry · doi:10.1177/070674371005500803 · Cited by 301
Meyer, U., Schwarz, M., & Müller, N. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.06.003 · Cited by 262
Potential metabolite markers of schizophrenia
Yang, J., Chen, T., Sun, L., Zhao, Z., Qi, X., Zhou, K., Cao, Y., Wang, X., Qiu, Y., Su, M., et al. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.131 · Cited by 251
Meyer, U., & Feldon, J. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.009 · Cited by 258
Neuromelanin-sensitive MRI as a noninvasive proxy measure of dopamine function in the human brain
Cassidy, C., Zucca, F. A., Girgis, R. R., Baker, S. C., Weinstein, J. J., Sharp, M. E., Bellei, C., Valmadre, A., Vanegas‐Arroyave, N., Kegeles, L. S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1807983116 · Cited by 245
Risk Factors for the Emergence of Psychotic Disorders in Adolescents With 22q11.2 Deletion Syndrome
Gothelf, D., Feinstein, C., Thompson, T., Gu, E., Penniman, L. C., Stone, E. V., Kwon, H., D, S. E. M., & Reiss, A. L. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.4.663 · Cited by 240
Fusar-Poli, P., Howes, O. D., Allen, P., Broome, M., Valli, I., Asselin, M.-C., Grasby, P. M., & McGuire, P. K. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.77 · Cited by 234
How Schizophrenia Develops: Cognitive and Brain Mechanisms Underlying Onset of Psychosis
Cannon, T. D. (2015) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2015.09.009 · Cited by 237
Lack of evidence to favor specific preventive interventions in psychosis: a network meta‐analysis
Davies, C., Cipriani, A., Ioannidis, J. P. A., Radua, J., Stahl, D., Provenzani, U., McGuire, P., & Fusar‐Poli, P. (2018) · World Psychiatry · doi:10.1002/wps.20526 · Cited by 229
Morrison, A. P., French, P., Parker, S., Roberts, M., Stevens, H., Bentall, R. P., & Lewis, S. W. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbl042 · Cited by 228
Addington, J., Epstein, I., Liu, L., French, P., Boydell, K. M., & Zipursky, R. B. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2010.10.015 · Cited by 226
Self-citationPreventing progression to first-episode psychosis in early initial prodromal states
Bechdolf, A., Wagner, M., Ruhrmann, S., Harrigan, S., Putzfeld, V., Pukrop, R., Brockhaus-Dumke, A., Berning, J., Janssen, B., Decker, P., et al. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.109.066357 · Cited by 224
Basic Symptoms and Ultrahigh Risk Criteria: Symptom Development in the Initial Prodromal State
Schultze‐Lutter, F., Ruhrmann, S., Berning, J., Maier, W., & Klosterkötter, J. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn072 · Cited by 224
van der Gaag, M., Nieman, D. H., Rietdijk, J., Dragt, S., Ising, H. K., Klaassen, R. M. C., Koeter, M., Cuijpers, P., Wunderink, L., & Linszen, D. H. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs105 · Cited by 209
Larson, M. K., Walker, E. F., & Compton, M. T. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.93 · Cited by 203
Miklowitz, D. J., O’Brien, M. P., Schlosser, D. A., Addington, J., Candan, K. A., Marshall, C., Domingues, I., Walsh, B. C., Zinberg, J. L., De Silva, S. D., et al. (2014) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2014.04.020 · Cited by 200
Self-citationA Social Deafferentation Hypothesis for Induction of Active Schizophrenia
Hoffman, R. E. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm079 · Cited by 199
Correll, C. U., Hauser, M., Auther, A. M., & Cornblatt, B. A. (2010) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2010.02235.x · Cited by 204
Early intervention in psychosis
Singh, S. P. (2010) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.109.075804 · Cited by 195
Wood, S. J., Pantelis, C., Velakoulis, D., Yücel, M., Fornito, A., & McGorry, P. D. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm149 · Cited by 195
Correll, C. U., Penzner, J. B., Frederickson, A. M., Richter, J. J., Auther, A. M., Smith, C. W., Kane, J. M., & Cornblatt, B. A. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm028 · Cited by 195
Light, G. A., Swerdlow, N. R., & BRAFF, D. L. (2007) · Journal of Cognitive Neuroscience · doi:10.1162/jocn.2007.19.10.1624 · Cited by 188
Prediction and Prevention of Psychosis in Youth at Clinical High Risk
Addington, J., & Heinssen, R. (2012) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032511-143146 · Cited by 189
Self-citationStratified medicine for mental disorders
Schumann, G., Binder, E. B., Holte, A., de Kloet, E. R., Oedegaard, K. J., Robbins, T. W., Walker-Tilley, T. R., Bitter, I., Brown, V. J., Buitelaar, J., et al. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.09.010 · Cited by 186
Cognitive behavioural therapy for psychosis prevention: a systematic review and meta-analysis
Hutton, P., & Taylor, P. J. (2014) · Psychological Medicine · doi:10.1017/s0033291713000354 · Cited by 184
Experience of trauma and conversion to psychosis in an ultra‐high‐risk (prodromal) group
Bechdolf, A., Thompson, A. D., Nelson, B., Cotton, S., Simmons, M. B., Amminger, G. P., Leicester, S., Francey, S. M., McNab, C., Krstev, H., et al. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2010.01542.x · Cited by 176
Tek, C., Küçükgöncü, S., Gülöksüz, S., Woods, S. W., Srihari, V. H., & Annamalai, A. (2015) · Early Intervention in Psychiatry · doi:10.1111/eip.12251 · Cited by 187
Self-citationNeuroinflammation and Oxidative Stress in Psychosis and Psychosis Risk
Barron, H., Hafizi, S., Andreazza, A. C., & Mizrahi, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030651 · Cited by 183
Preti, A., & Cella, M. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.07.026 · Cited by 167
The Aberrant Salience Inventory: A new measure of psychosis proneness.
Cicero, D. C., Kerns, J. G., & McCarthy, D. M. (2010) · Psychological Assessment · doi:10.1037/a0019913 · Cited by 176
Early Detection and Preventive Intervention in Schizophrenia: From Fantasy to Reality
Lieberman, J. A., Small, S. A., & Girgis, R. R. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19080865 · Cited by 165
The Economic Analysis of Prevention in Mental Health Programs
Mihalopoulos, C., Vos, T., Pirkis, J., & Carter, R. (2011) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032210-104601 · Cited by 159
Functional neuroimaging in schizophrenia: diagnosis and drug discovery
McGuire, P. K., Howes, O. D., Stone, J. M., & Fusar‐Poli, P. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.11.005 · Cited by 157
Ultra high-risk state for psychosis and non-transition: A systematic review
Simon, A. E., Velthorst, E., Nieman, D. H., LINSZEN, D. H., Umbricht, D., & de Haan, L. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.07.002 · Cited by 155
Ruhrmann, S., Schultze-Lutter, F., & Klosterkötter, J. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.03.015 · Cited by 147
Mei, C., van der Gaag, M., Nelson, B., Smit, F., Yuen, H. P., Berger, M., Krcmar, M., French, P., Amminger, G. P., Bechdolf, A., et al. (2021) · Clinical Psychology Review · doi:10.1016/j.cpr.2021.102005 · Cited by 143
Piontkewitz, Y., Assaf, Y., & Weiner, I. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.07.005 · Cited by 147
Development of social functioning in preschizophrenia children and adolescents: A systematic review.
Tarbox, S. I., & Pogue‐Geile, M. F. (2008) · Psychological Bulletin · doi:10.1037/0033-2909.34.4.561 · Cited by 147
Piontkewitz, Y., Arad, M., & Weiner, I. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq040 · Cited by 146
Glutamatergic dysfunction in schizophrenia: From basic neuroscience to clinical psychopharmacology
Paz, R. D., Tardito, S., Atzori, M., & Tseng, K. Y. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.06.005 · Cited by 145
The psychosis threshold in Ultra High Risk (prodromal) research: Is it valid?
Yung, A. R., Nelson, B., Thompson, A. D., & Wood, S. J. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.03.014 · Cited by 143
Randomized Controlled Trial of Interventions for Young People at Ultra-High Risk of Psychosis
McGorry, P. D., Nelson, B., Phillips, L., Yuen, H. P., Francey, S. M., Thampi, A., Berger, G. E., Amminger, G. P., Simmons, M. B., Kelly, D., et al. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m07785 · Cited by 144
Mossaheb, N., Becker, J., Schaefer, M. R., Klier, C. M., Schloegelhofer, M., Papageorgiou, K., & Amminger, G. P. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.08.008 · Cited by 142
Baharnoori, M., Bhardwaj, S. K., & Srivastava, L. K. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq098 · Cited by 145
European Psychiatric Association (EPA) guidance on prevention of mental disorders
Campion, J., Bhui, K. S., & Bhugra, D. (2012) · European Psychiatry · doi:10.1016/j.eurpsy.2011.10.004 · Cited by 138
Effectiveness of early intervention in psychosis
Killackey, E. J., & Yung, A. R. (2007) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e328017f67d · Cited by 133
Bechdolf, A., Nelson, B., Cotton, S. M., Chanen, A., Thompson, A., Kettle, J., Conus, P., Amminger, G. P., Yung, A. R., Berk, M., et al. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.06.016 · Cited by 131
The case for including Attenuated Psychotic Symptoms Syndrome in DSM-5 as a psychosis risk syndrome
Woods, S. W., Walsh, B. C., Saksa, J. R., & McGlashan, T. H. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.08.012 · Cited by 130
Self-citationThe psychosis risk syndrome and its proposed inclusion in the DSM-V: A risk–benefit analysis
Corcoran, C. M., First, M. B., & Cornblatt, B. A. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.03.018 · Cited by 129
Phillips, L., McGorry, P. D., Yuen, H. P., WARD, J., DONOVAN, K., Kelly, D. J., Francey, S., & Yung, A. R. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.05.018 · Cited by 129
Neuroimaging and emerging psychotic disorders: The Melbourne ultra-high risk studies
Pantelis, C., Velakoulis, D., Wood, S. J., Yücel, M., Yung, A. R., Phillips, L., Sun, D.-Q., & McGorry, P. D. (2007) · International Review of Psychiatry · doi:10.1080/09540260701512079 · Cited by 128
CSF Metabolic and Proteomic Profiles in Patients Prodromal for Psychosis
Huang, J. T.-J., Leweke, F. M., Tsang, T. M., Koethe, D., Kranaster, L., Gerth, C. W., Gross, S., Schreiber, D., Ruhrmann, S., Schultze‐Lutter, F., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000756 · Cited by 127
Aripiprazole in the treatment of the psychosis prodrome
Woods, S. W., Tully, E. M., Walsh, B. C., Hawkins, K. A., Callahan, J. L., Cohen, S. J., Mathalon, D. H., Miller, T. J., & McGlashan, T. H. (2007) · The British Journal of Psychiatry · doi:10.1192/bjp.191.51.s96 · Cited by 126
Self-citationGomes, F. V., Rincón‐Cortés, M., & Grace, A. A. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.05.030 · Cited by 131
Moreno, J. L., Kurita, M., Holloway, T. D., López, J., Cadagan, R., Martínez‐Sobrido, L., García‐Sastre, A., & González‐Maeso, J. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.4230-10.2011 · Cited by 123
Economic impact of early intervention in people at high risk of psychosis
Valmaggia, L., McCrone, P., Knapp, M. R. J., Woolley, J. B., Broome, M. R., Tabraham, P., Johns, L., Prescott, C., Bramon, E., Lappin, J., et al. (2009) · Psychological Medicine · doi:10.1017/s0033291709005613 · Cited by 118
Lebow, J. R., Sim, L. A., Erwin, P. J., & Murad, M. H. (2012) · International Journal of Eating Disorders · doi:10.1002/eat.22059 · Cited by 117
McFarlane, W. R., Levin, B. L., Travis, L., Lucas, F. L., Lynch, S., Verdi, M., Williams, D. L., Adelsheim, S. N., Calkins, R., Carter, C. S., et al. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu108 · Cited by 117
Meyer, U., Spoerri, E., Yee, B. K., Schwarz, M., & Feldon, J. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn131 · Cited by 117
Time-Lapse Mapping of Cortical Changes in Schizophrenia with Different Treatments
Thompson, P. M., Bartzokis, G., Hayashi, K. M., Klunder, A. D., Lu, P. H., Edwards, N. J., Hong, M., Yu, M. A., Geaga, J. A., Toga, A. W., et al. (2008) · Cerebral Cortex · doi:10.1093/cercor/bhn152 · Cited by 113
Self-citationCalarge, C. A., Ación, L., Kuperman, S., Tansey, M., & Schlechte, J. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2008.007 · Cited by 110
What drives poor functioning in the at-risk mental state? A systematic review
Cotter, J., Drake, R., Bucci, S., Firth, J., Edge, D., & Yung, A. R. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.09.012 · Cited by 111
Antipsychotics for Children and Young Adults: A Comparative Effectiveness Review
Seida, J. C., Schouten, J. R., Boylan, K., Newton, A. S., Mousavi, S. S., Beaith, A., Vandermeer, B., Dryden, D. M., & CARREY, N. J. (2012) · PEDIATRICS · doi:10.1542/peds.2011-2158 · Cited by 111
Sandhya, L., Devi Sreenivasan, N., Goenka, L., Dubashi, B., Kayal, S., Solaiappan, M., Govindarajalou, R., KT, H., & Ganesan, P. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01997 · Cited by 115
Preventive Treatments for Psychosis: Umbrella Review (Just the Evidence)
Fusar-Poli, P., Davies, C., Solmi, M., Brondino, N., De Micheli, A., Kotlicka-Antczak, M., Shin, J. I., & Radua, J. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00764 · Cited by 108
Metadata
- Authors
- McGlashan, T. H., Zipursky, R. B., Perkins, D., Addington, J., Miller, T., Woods, S. W., A. Hawkins, K., E. Hoffman, R., Preda, A., Epstein, I., Addington, D., Lindborg, S., Trzaskoma, Q., Tohen, M., & Breier, A.
- Affiliations
- Yale University (US)
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2006-05
- Volume
- 163
- Issue
- 5
- Pages
- 790-799
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2121366540
- Cited by
- 556
- References
- 30
- Citations by year
- 2026: 4 · 2025: 11 · 2024: 12 · 2023: 7 · 2022: 6 · 2021: 18 · 2020: 21 · 2019: 18 · 2018: 10 · 2017: 12 · 2016: 31 · 2015: 26 · 2014: 28 · 2013: 38 · 2012: 47
- FWCI
- 32.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- Funders
- Eli Lilly and Company
- University of Toronto
- National Institutes of Health (5r24mh054446-05)
- National Institute of Mental Health (K05 MH-01654, MH01654, 1 K23 MH01905, K23MH001905, R01MH067073, R01 MH-67073, R24-MH-54446, R02 MH-50557, K05MH001654)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
- Keywords
- olanzapine, transition to psychosis, weight gain, atypical antipsychotics
- MeSH terms
- Olanzapine, Adolescent, Ambulatory Care, Benzodiazepines, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Obesity, Placebos, Psychiatric Status Rating Scales, Schizophrenia, Schizophrenic Psychology, Severity of Illness Index, Antipsychotic Agents, Weight Gain, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
